Pallas Capital Advisors LLC Invests $113,000 in Sera Prognostics, Inc. (NASDAQ:SERA)

Pallas Capital Advisors LLC bought a new position in shares of Sera Prognostics, Inc. (NASDAQ:SERA) during the fourth quarter, Holdings Channel.com reports. The fund bought 13,851 shares of the company’s stock, valued at approximately $113,000.

Other large investors have also added to or reduced their stakes in the company. Quest Partners LLC raised its holdings in Sera Prognostics by 533.5% in the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock valued at $50,000 after acquiring an additional 5,415 shares during the period. SG Americas Securities LLC bought a new position in shares of Sera Prognostics during the third quarter worth approximately $78,000. The Manufacturers Life Insurance Company bought a new position in shares of Sera Prognostics during the second quarter worth approximately $68,000. Prime Capital Investment Advisors LLC acquired a new stake in Sera Prognostics during the 3rd quarter worth approximately $104,000. Finally, Jane Street Group LLC boosted its stake in Sera Prognostics by 24.8% in the 3rd quarter. Jane Street Group LLC now owns 14,225 shares of the company’s stock valued at $111,000 after purchasing an additional 2,826 shares during the period. Institutional investors own 54.64% of the company’s stock.

Sera Prognostics Price Performance

SERA stock opened at $6.61 on Thursday. Sera Prognostics, Inc. has a fifty-two week low of $4.98 and a fifty-two week high of $12.35. The stock has a market capitalization of $223.23 million, a price-to-earnings ratio of -6.68 and a beta of 0.86. The business’s fifty day moving average price is $7.44 and its two-hundred day moving average price is $7.31.

Sera Prognostics (NASDAQ:SERA) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.09 million. During the same quarter last year, the company posted ($0.23) earnings per share. Research analysts expect that Sera Prognostics, Inc. will post -0.96 EPS for the current year.

Insider Activity

In other news, CEO Zhenya Lindgardt sold 12,075 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $7.32, for a total transaction of $88,389.00. Following the completion of the transaction, the chief executive officer now directly owns 819,758 shares in the company, valued at approximately $6,000,628.56. This represents a 1.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Robert Gardner Harrison sold 14,209 shares of the business’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $7.39, for a total value of $105,004.51. Following the sale, the insider now owns 116,837 shares in the company, valued at approximately $863,425.43. This trade represents a 10.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 93,215 shares of company stock worth $666,835. Corporate insiders own 15.80% of the company’s stock.

Sera Prognostics Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.